Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO

Investors who purchased shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023, and December 26, 2025, are urged to contact The Gross Law Firm by April 7, 2026, to explore their legal rights surrounding potential securities violations. The firm seeks to represent individuals who may have suffered financial losses due to alleged misleading practices by Inovio’s management during this specified time period.

The allegations against Inovio center on claims that the company's public statements misrepresented crucial information regarding its CELLECTRA device manufacturing and its lead product candidate, INO-3107. It is asserted that deficiencies existed in the manufacturing process, which hindered the feasibility of submitting a Biologics License Application (BLA) to the FDA by mid-2024. Furthermore, it is claimed that Inovio lacked sufficient evidence to support INO-3107's potential for FDA accelerated approval or priority review, resulting in an inflated perception of the candidate's regulatory and commercial viability.

The deadline for shareholders to be considered as potential lead plaintiffs in any upcoming class action lawsuit is April 7, 2026. Participants can register without any financial obligation, allowing them to stay informed about the progress of the case through a monitoring system provided by the firm.

The Gross Law Firm, known for its focus on protecting investor rights, emphasizes the importance of addressing deceptive corporate practices. Shareholders of Inovio are encouraged to act promptly to secure their positions in this emerging legal matter and can reach The Gross Law Firm directly through their website or contact information provided in the announcement.

Investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) are facing potential legal ramifications stemming from allegations of misleading statements regarding the company's lead product candidate, INO-3107. The class period, which spans from October 10, 2023, to December 26, 2025, highlights key concerns about the manufacturing deficiencies of Inovio's CELLECTRA device and the company's capacity to secure necessary regulatory approvals. As a result, investors who have acquired shares during this timeframe are strongly advised to consult with The Gross Law Firm before the approaching deadline of April 7, 2026.

Given the backdrop of these allegations, investors must reevaluate their positions concerning INO. Should these claims hold merit, the implications could be materially damaging, not only to Inovio's market standing but also to the valuation of its shares. The firm's failure to disclose pertinent information regarding INO-3107 could lead to an unfavorable outcome if the case proceeds, possibly resulting in financial losses for shareholders.

For those who purchased INO during the specified class period, proactive engagement is essential. Registering with The Gross Law Firm provides investors with a pathway to potentially recover losses incurred as a consequence of the firm's alleged misleading actions. Enrolling in their portfolio monitoring system will keep investors informed of any developments, ensuring that they remain aligned with ongoing legal proceedings.

With Inovio navigating significant challenges and regulatory hurdles, shareholders should remain vigilant. By consulting The Gross Law Firm, investors not only protect their rights but also take an important step toward understanding their options in the event of unfavorable judicial outcomes. In this fluctuating market, informed decision-making is paramount.